Mizuho Boosts PT on Clovis Oncology (CLVS) to $23 Following Rucaparib NDA Approval

August 24, 2016 6:34 AM EDT
Get Alerts CLVS Hot Sheet
Price: $56.26 --0%

Rating Summary:
    5 Buy, 8 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 3 | Down: 5 | New: 17
Trade CLVS Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Mizuho boosts its price taget on Neutral-rated Clovis Oncology (Nasdaq: CLVS) from $15 to $23 after the company announced that the U.S. Food and Drug Administration (FDA) has accepted Clovis’ New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application with a Prescription Drug User Fee Act (PDUFA) date of February 23, 2017.

The firm commented, We're becoming more positive on the name, especially with M&A news flow making the headlines. However, with a number of competitive PARP data releases coming up, and relatively limited data from CLVS before a late February PDUFA date, we stay Neutral.

For an analyst ratings summary and ratings history on Clovis Oncology click here. For more ratings news on Clovis Oncology click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities


Add Your Comment